1-3 of 3
Alain Thibault, MD
Close
Sort by
Journal Articles

Tipifarnib (Zarnestra, R115777) as Maintenance Therapy for Adults in Complete Remission (CR) Following Induction and Consolidation Therapies for Poor-Risk Acute Myelogenous Leukemia (AML): A Phase II Trial.

Judith E. Karp, MD, Ivana Gojo, MD, Jacqueline Greer, R.N., B. Douglas Smith, MD, Maureen Klein, R.N., Jeffery E. Lancet, MD, Steven D. Gore, MD, Lawrence Morris, MD, Alain Thibault, MD, Mary Ellen Rybak, MD, John J. Wright, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 2783.
https://doi.org/10.1182/blood.V106.11.2783.2783
Published: 2005
Journal Articles

Gene Expression Profiling Predictive of Tipifarnib (ZARNESTRA ® , R115777) Response in Patients with Newly Diagnosed Acute Myeloid Leukemia.

Mitch Raponi, MD, Yi Zhang, PhD, Tim Jatkoe, MD, Jack Yu, PhD, Grace Lee, MD, Jeffrey E. Lancet, MD, Judith E. Karp, MD, Alain Thibault, MD, Yixin Wang
Journal: Blood
Blood (2005) 106 (11): 2785.
https://doi.org/10.1182/blood.V106.11.2785.2785
Published: 2005
Journal Articles

Tipifarnib (ZARNESTRA TM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.

Jeffrey E. Lancet, MD, Jason Gotlib, MD, Ivana Gojo, MD, Eric J. Feldman, MD, Lawrence Morris, MD, Alain Thibault, MD, Jane L. Liesveld, MD, Jacqueline Greer, RN, Kathleen Dugan, RN, Mitch Raponi, PhD, John J. Wright, MD, PhD, Peter L. Greenberg, MD, Judith E. Karp, MD
Journal: Blood
Blood (2004) 104 (11): 874.
https://doi.org/10.1182/blood.V104.11.874.874
Published: 2004